Effects of cardiovascular single pill combinations compared with identical multi-pill therapies on healthcare cost and utilization in Germany

Author:

Wilke Thomas1ORCID,Weisser Burkhard2,Predel Hans-Georg3,Schmieder Roland E4,Wassmann Sven5,Gillessen Anton6,Blettenberg Jörg7,Maywald Ulf8,Randerath Olaf9,Müller Sabrina10,Böhm Michael11

Affiliation:

1. Institute for Pharmacoeconomics & drug logistics, University of Wismar, 23966, Germany

2. Institute of Sports Science, Christian-Albrechts-University of Kiel, Kiel, 24118, Germany

3. Institute of Cardiology & Sports Medicine, German Sport University, Cologne, 50933, Germany

4. Department of Nephrology & Hypertension, University Hospital Erlangen, Friedrich Alexander University Erlangen Nürnberg, Erlangen, 91054, Germany

5. Department of Inner medicine & Cardiology, Cardiology Pasing, Munich, 81241, Germany & Faculty of Medicine, University of the Saarland, Homburg/Saar, 66123, Germany

6. Department of Internal Medicine, Herz-Jesu-Hospital, Münster, 48165, Germany

7. Practice Dr. J.Blettenberg, Lindlar, 51789, Germany

8. Drug department, AOK PLUS, Dresden, 01067, Germany

9. Medical Department, APONTIS PHARMA Germany GmbH & Co. KG, Monheim, 40789, Germany

10. Department of Real-World Evidence & Evidence Synthesis, Ingress-Health HWM GmbH, Wismar, 23966, Germany

11. Clinic for Internal Medicine III, University clinic of Saarlandes, Saarland University, Homburg/Saar, Germany

Abstract

Aim: This study assessed whether a single pill combination (SPC) is associated with lower direct healthcare costs. Materials & methods: Anonymized claims data of patients ≥18 years treated with drugs for cardiovascular (CV)-related diseases either as a single pill combination or multi-pill combination (follow-up to 1 year) were evaluated. After propensity score matching, 59,336 out of 1,369,840 patients were analyzed. Results: In all cohorts, patients receiving a single pill combination had a lower frequency of general practitioner and specialist visits. The patients also had a significantly lower ratio of all-cause hospitalization days and number of CV-related prescriptions as well as all-cause prescriptions (with one exception) compared with those receiving a multi-pill combination. Conclusion: Direct CV-related costs were significantly lower in four out of seven comparisons, with a trend toward lower costs in the other three comparisons.

Funder

APONTIS PHARMA Deutschland GmbH & Co. KG

Publisher

Becaris Publishing Limited

Subject

Health Policy

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3